Karen E Hayes

Modulation Therapeutics, Inc.

$1,245,154

Attributed

$3,353,615

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.3M · FY2019–25

$2M$1.5M$1M$500K$0

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$3,353,615 · 2

By mechanism

R44$3,353,615 · 2

Top collaborators

Most similar at Modulation Therapeutics, Inc.

Same institution · by research overlap

Lori Hazlehurst$1,674,270
Werner Geldenhuys$2,374,551
Winston Tan$863,307
Karen Hayes$1,000,000

Others in their field

Other Emerging Leaders on “Synergism”

Stephen F Kry · University Of Tx Md Anderson Can Ctr$28,888,963
Mark Brian Reed · San Diego State University$13,246,314
Ashok Kumar Krishnamurthy · Univ Of North Carolina Chapel Hill$10,798,287
Crystal Mackall · Children'S Hosp Of Philadelphia$10,785,733
Bronwen Shaw · Medical College Of Wisconsin$10,328,749
Terry Roemer · Prokaryotics, Inc.$9,636,629

Research focus

SynergismMalignant NeoplasmsPhase I Clinical TrialsDosePhase Iii Clinical TrialsCanis FamiliarisMouse ModelPathway InteractionsResponse BiomarkerTumorSmall Business Innovation Research GrantPredictive MarkerDesignCell DeathDrug ResistanceAttenuationApoptoticAcidsAnti-Pd1 TherapyCancer ImmunotherapyDeprivationCalreticulinAnti-Pd1 AntibodiesCancer Cell

Grant awards (5)

Modulation of cancer induced immune suppression via inhibition of SCD1$217,685

R44 · FY2025 · CA · contact PI

Modulation of cancer induced immune suppression via inhibition of SCD1$670,441

R44 · FY2024 · CA · contact PI

Modulation of cancer induced immune suppression via inhibition of SCD1$1,301,808

R44 · FY2023 · CA · contact PI

Modulation of cancer induced immune suppression via inhibition of SCD1$399,986

R44 · FY2022 · CA · contact PI

Development of PEGylated MTI-101 for the treatment of relapsed Myeloma$763,695

R44 · FY2019 · CA · contact PI